Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma

  • PLoS One. 2022 Feb 14;17(2):e0263822. doi: 10.1371/journal.pone.0263822.
Erica A Power  1  2 Jenelys Fernandez-Torres  1 Liang Zhang  1 Ruiyi Yaun  1 Fabrice Lucien  3 David J Daniels  1  4
Affiliations
  • 1. Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, United States of America.
  • 2. Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, United States of America.
  • 3. Department of Urology, Mayo Clinic, Rochester, MN, United States of America.
  • 4. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States of America.
Abstract

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain tumor. While there are a number of in vivo rodent models for evaluating tumor biology and response to therapy, these models require significant time and resources. Here, we established the chick-embryo chorioallantoic (CAM) assay as an affordable and time efficient xenograft model for testing a variety of treatment approaches for DIPG. We found that patient-derived DIPG tumors develop in the CAM and maintain the same genetic and epigenetic characteristics of native DIPG tumors. We monitored tumor response to pharmaco- and radiation therapy by 3-D ultrasound volumetric and vasculature analysis. In this study, we established and validated the CAM model as a potential intermediate xenograft model for DIPG and its use for testing novel treatment approaches that include pharmacotherapy or radiation.

Products